Venture Life Group (VLG.L) Stock Price
Venture Life Group Price
Over the last 15 years Venture Life Group grew revenue by 47.7% annually, reaching 35.17 M GBP. Earnings per share have grown at 49.4% per year over the last 7 years. For Venture Life Group, the net margin of 17.4% is up versus 7.3% a few years ago. At today's price the dividend yield works out to roughly 0.06%. The payout ratio is around 15% of earnings. The consensus 12-month price target for Venture Life Group is 102.00 GBP, about 14,682.6% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.
Venture Life Group stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Venture Life Group business model & stock analysis
Frequently asked questions about Venture Life Group
The business model of Venture Life Group PLC focuses on the development, manufacturing, and commercialization of innovative products in the healthcare sector. By leveraging their expertise and strategic partnerships, Venture Life Group PLC creates and sells a range of medical devices, cosmetics, and nutritional products. They aim to improve the quality of life for their customers by providing high-quality, scientifically validated solutions. Through continuous research and development, Venture Life Group PLC stays at the forefront of the industry, ensuring their products meet the evolving needs of healthcare professionals and end-users.
Venture Life Group PLC is primarily active in the healthcare and consumer wellness industries. The company focuses on developing, manufacturing, and marketing a wide range of innovative products in these sectors. With a strong emphasis on quality and customer satisfaction, Venture Life Group PLC aims to meet the diverse needs of individuals across various healthcare segments. This dedication has positioned the company as a leading player in the healthcare industry, providing effective solutions and improving the well-being of consumers worldwide.
The main competitors of Venture Life Group PLC in the market are companies like Johnson & Johnson, Procter & Gamble, and Unilever.
Venture Life Group PLC is a UK-based international consumer healthcare company. Founded in 2010, the company focuses on the development, manufacturing, and commercialization of innovative products for the self-care market. Venture Life Group PLC offers a wide range of products, including medical devices, oral care products, and dermatological solutions. With a strong track record of delivering high-quality products, the company has expanded its presence across Europe and other international markets. Venture Life Group PLC's commitment to innovation and its strategic partnerships with leading healthcare companies have contributed to its success in providing effective and accessible healthcare solutions globally.
Venture Life Group PLC has achieved several significant milestones throughout its journey. The company successfully expanded its product portfolio by launching innovative brands and entering into strategic partnerships. They have also demonstrated impressive market growth and secured distribution agreements in multiple regions. Moreover, Venture Life Group PLC has consistently maintained a strong financial position, generating substantial revenue and delivering impressive shareholder returns. These achievements highlight the company's successful track record and commitment to driving growth and excellence in the healthcare industry.
Venture Life Group PLC is primarily present in multiple countries and regions. The company has an extensive international presence with its operations spanning across Europe, Asia, and the Middle East. Some key countries where Venture Life Group PLC operates include the United Kingdom, Italy, Spain, Portugal, France, Germany, the Netherlands, China, and the United Arab Emirates. With its focus on global expansion, Venture Life Group PLC continues to establish a strong presence in these regions, combining its expertise in the healthcare and consumer wellness sectors to provide innovative solutions to customers worldwide.
Venture Life Group PLC is a company that values innovation, excellence, and integrity in all aspects of its operations. Their corporate philosophy is centered around delivering high-quality healthcare and personal care products to customers worldwide. With a focus on research and development, Venture Life Group PLC aims to enhance people's lives through their innovative product offerings. Their commitment to ethical practices and sustainable growth makes them a trusted choice for customers seeking reliable healthcare solutions. Venture Life Group PLC's dedication to customer satisfaction and continuous improvement sets them apart in the industry, making them a leading player in the global healthcare market.
Analysts currently set an average price target of 102.00 GBP for the Venture Life Group stock (median: 102.00 GBP), implying +47.8 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Venture Life Group stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Venture Life Group to generate revenue of 42.40 M GBP and earnings per share of 0.00 GBP.
Converted at the current exchange rate, the Venture Life Group share trades at 0.82 EUR (0.69 GBP).
The Venture Life Group share (VLG.L) is listed on 3 stock exchanges, including: London (VLG.L), Frankfurt (17V.F).
The Venture Life Group PLC is a global consumer goods company in the health and wellness sector, focusing on the development and marketing of products for the over-the-counter (OTC) and professional markets. The company operates in four business segments: the dermatology category, the oral health category, the animal health category, and the lifestyle products category. The dermatology category develops and distributes products for the treatment of skin problems such as acne, eczema, psoriasis, and skin infections. Some of the brand-name products include DermaSilk, UltraDEX, and New Skin. In the oral health category, Venture Life produces mouthwashes and toothpastes tailored to specific needs. They have several brands in their portfolio, including UltraDEX, NeuBrite, and Dentyl. The animal health category includes a wide range of health and wellness products for pets. The product range includes shampoos, lotions, wound creams, vitamin supplements, and flea and tick treatments. The products are available under the brand names Proderm, Vetruus, and UltraBeau. Lifestyle products are also offered, including Venetiaurum, a dietary supplement for skin, hair, and nails; Kultura, a probiotic for the gut; and Lubatti, a luxurious beauty salon. Venture Life Group's business model is based on product development and distribution, with a focus on innovation and quality. The company utilizes an efficient and agile business model that accelerates the development process from idea to market launch and reduces administrative costs. Venture Life works closely with research and development departments as well as external partner companies to leverage innovative technologies, active ingredients, and platforms for the development of new products. The company also places great importance on its international distribution channels and works with leading retailers worldwide to promote the distribution of its products. Online sales platforms also play a major role in the business model, including the company's own website, which is available to customers in the EU, North America, and Asia. Venture Life Group PLC is a rapidly growing company with strong brands and a forward-thinking business model. It is a leading provider of health and wellness products for consumers and the professional market.
The expected revenue of Venture Life Group is 42.40 M GBP. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Venture Life Group is 69,696.17 GBP. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Venture Life Group is currently 1,360.55. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Venture Life Group stock.
The price-to-sales ratio (P/S) of Venture Life Group is currently 2.24. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Venture Life Group stock.
The Eulerpool Quality Score for Venture Life Group is 4/10.
The ISIN of Venture Life Group is GB00BFPM8908. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Venture Life Group is A110ZQ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Venture Life Group is VLG.L. The ticker symbol is used to trade Venture Life Group shares on the stock exchange.
Venture Life Group stock
Venture Life Group Peer Group
Venture Life Group Ticker
Venture Life Group FIGI
All fundamentals and in-depth analysis of Venture Life Group
Our stock analysis for Venture Life Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Venture Life Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.